Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARANASDAQ:FNCHNASDAQ:FRTXNASDAQ:GBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4123,063 shs237,144 shsFNCHFinch Therapeutics Group$13.20$13.17$1.10▼$15.85$21.20M1.262,174 shs45 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsGBIOGeneration Bio$0.30-15.4%$0.39$0.30▼$3.65$20.14M2.66371,950 shs7.36 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%+3.30%+52.87%FNCHFinch Therapeutics Group0.00%-1.86%-3.65%-6.10%+877.78%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%+5.06%GBIOGeneration Bio-15.40%-20.95%-18.06%-29.78%-89.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics0.3047 of 5 stars0.00.00.04.20.60.80.0FNCHFinch Therapeutics Group0.3488 of 5 stars0.03.00.00.00.01.70.6FRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGBIOGeneration Bio3.541 of 5 stars3.53.00.00.02.63.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 0.00N/AN/AN/AFNCHFinch Therapeutics Group 0.00N/AN/AN/AFRTXFresh Tracks Therapeutics 0.00N/AN/AN/AGBIOGeneration Bio 3.00Buy$7.332,341.19% UpsideCurrent Analyst Ratings BreakdownLatest FRTX, CARA, GBIO, and FNCH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/10/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00FNCHFinch Therapeutics Group$110K192.72N/AN/A$14.25 per share0.93FRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56GBIOGeneration Bio$19.89M1.01N/AN/A$1.29 per share0.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/AFNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/AGBIOGeneration Bio-$131.67M-$1.08N/AN/AN/A-292.92%-75.84%-30.40%8/6/2025 (Estimated)Latest FRTX, CARA, GBIO, and FNCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025GBIOGeneration Bio-$0.25-$0.22+$0.03-$0.22$1.70 million$8.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AGBIOGeneration BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71FNCHFinch Therapeutics GroupN/A3.873.87FRTXFresh Tracks TherapeuticsN/AN/AN/AGBIOGeneration BioN/A8.438.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%FNCHFinch Therapeutics Group21.77%FRTXFresh Tracks Therapeutics25.04%GBIOGeneration Bio95.22%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%FNCHFinch Therapeutics Group44.90%FRTXFresh Tracks Therapeutics0.23%GBIOGeneration Bio21.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableGBIOGeneration Bio15067.04 million52.42 millionOptionableFRTX, CARA, GBIO, and FNCH HeadlinesRecent News About These CompaniesGBIO Generation Bio Co. - Seeking AlphaJune 26 at 7:43 AM | seekingalpha.comWe're Keeping An Eye On Generation Bio's (NASDAQ:GBIO) Cash Burn RateJune 25 at 8:42 AM | finance.yahoo.comGeneration Bio to Present at the 2025 Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comGeneration Bio Co.: Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial ResultsMay 26, 2025 | finanznachrichten.deGeneration Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2025 | zacks.comGeneration Bio Reports Recent Business Highlights and First Quarter 2025 Financial ResultsMay 7, 2025 | globenewswire.comGeneration Bio to Present at the Needham 24th Annual Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comWedbush Keeps Their Buy Rating on Generation Bio (GBIO)March 18, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN) and Generation Bio (GBIO)March 17, 2025 | markets.businessinsider.comGeneration Bio Co. Advances in Autoimmune TherapeuticsMarch 14, 2025 | tipranks.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Sutro Biopharma (STRO) and Generation Bio (GBIO)March 13, 2025 | markets.businessinsider.comGeneration Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue EstimatesMarch 13, 2025 | zacks.comGeneration Bio Co. Advances T Cell-Selective siRNA Therapeutics for Autoimmune Diseases, Announces Robust Financial PositionMarch 13, 2025 | quiverquant.comQGeneration Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial ResultsMarch 13, 2025 | globenewswire.comGeneration Bio to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | globenewswire.comGeneration Bio stock hits 52-week low at $0.66February 11, 2025 | msn.comTubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.February 6, 2025 | businesswire.comGeneration Bio participates in a conference call with JPMorganFebruary 3, 2025 | markets.businessinsider.comWhat’s Fueling Generation Bio Co (GBIO) Stock’s -61.35% Loss Below Its 200-Day SMA?January 18, 2025 | bovnews.comBWill Generation Bio (NASDAQ:GBIO) Spend Its Cash Wisely?January 17, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFRTX, CARA, GBIO, and FNCH Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Finch Therapeutics Group NASDAQ:FNCH$13.20 0.00 (0.00%) As of 06/27/2025Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.Generation Bio NASDAQ:GBIO$0.30 -0.05 (-15.40%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.36 +0.06 (+18.51%) As of 06/27/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
